Literature DB >> 21983497

Medication adherence and subjective weight perception in patients with first-episode psychotic disorder.

Mimi M C Wong1, E Y H Chen, Simon S Y Lui, Steve Tso.   

Abstract

INTRODUCTION: Medication adherence is critical to the management of psychotic disorder. Different factors associated with medication adherence have been investigated in previous studies. However, the association with subjective weight perception, which is related to the weight gain side effect of antipsychotics, has not been thoroughly investigated. Subjective weight perception may not equal objective weight status. This study tests the hypothesis that medication adherence is related to subjective weight perception in a group of patients with first-episode psychotic disorder who have taken antipsychotics for one year.
METHODS: This study recruited 160 participants with one-year histories of first-episode psychotic disorder and measured their actual and perceived weights, amount of weight gain in the past year, body size satisfaction and medication adherence levels. The associations between medication adherence and both the actual and perceived weight status were analyzed controlling for other confounding factors including insight, drug attitude, illness severity and other medication side effects.
RESULTS: Stepwise multiple regression analysis found that the participants' perceived weight status, negative attitude toward their drugs and insight were the major factors associated with poor medication adherence. Of the participants who perceived themselves as being overweight, 86% believed that antipsychotics were responsible. Among those who had such beliefs, 72% had reduced their antipsychotic dosages on their own. About half of the participants had gained more than 7% of their baseline weight and 43.1% of the participants were found to be overweight after one year of treatment with antipsychotics.
CONCLUSIONS: The results of this study indicate that medication adherence is associated with perceived weight status. Healthcare professionals should be aware of this relationship and address this issue early in the management of patients. Apart from weight management programs, education on a correct weight perception should be carried out with the promotion of proper drug attitudes and better insight for the improvement of medication adherence in the early course of psychotic disorder.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983497     DOI: 10.3371/CSRP.5.3.3

Source DB:  PubMed          Journal:  Clin Schizophr Relat Psychoses        ISSN: 1935-1232


  16 in total

1.  Gender differences in antipsychotics prescribed to veterans with serious mental illness.

Authors:  Elana Schwartz; Melanie Charlotte; Eric Slade; Deborah Medoff; Lan Li; Lisa Dixon; Amy Kilbourne; Julie Kreyenbuhl
Journal:  Gen Hosp Psychiatry       Date:  2015-04-01       Impact factor: 3.238

2.  A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity.

Authors:  Zachary D Erickson; Crystal L Kwan; Hollie A Gelberg; Irina Y Arnold; Valery Chamberlin; Jennifer A Rosen; Chandresh Shah; Charles T Nguyen; Gerhard Hellemann; Dixie R Aragaki; Charles F Kunkel; Melissa M Lewis; Neena Sachinvala; Patrick A Sonza; Joseph M Pierre; Donna Ames
Journal:  J Gen Intern Med       Date:  2017-04       Impact factor: 5.128

3.  Gender differences in mood stabilizer medications prescribed to Veterans with serious mental illness.

Authors:  Melanie Charlotte; Elana Schwartz; Eric Slade; Deborah Medoff; Lan Li; Lisa Dixon; Amy M Kilbourne; Julie Kreyenbuhl
Journal:  J Affect Disord       Date:  2015-09-03       Impact factor: 4.839

4.  SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects.

Authors:  Peter M Haddad; W Wolfgang Fleischhacker; Joseph Peuskens; Roberto Cavallaro; Michael Ej Lean; Margarita Morozova; Gavin Reynolds; Jean-Michel Azorin; Pierre Thomas; Hans-Jürgen Möller
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

5.  Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.

Authors:  Jonathan M Meyer; Yongcai Mao; Andrei Pikalov; Josephine Cucchiaro; Antony Loebel
Journal:  Int Clin Psychopharmacol       Date:  2015-11       Impact factor: 1.659

Review 6.  Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.

Authors:  Peter M Haddad; Cecilia Brain; Jan Scott
Journal:  Patient Relat Outcome Meas       Date:  2014-06-23

7.  Histaminergic system in brain disorders: lessons from the translational approach and future perspectives.

Authors:  Diego Baronio; Taylor Gonchoroski; Kamila Castro; Geancarlo Zanatta; Carmem Gottfried; Rudimar Riesgo
Journal:  Ann Gen Psychiatry       Date:  2014-11-18       Impact factor: 3.455

8.  Validation of the Medication Adherence Rating Scale in homeless patients with schizophrenia: Results from the French Housing First experience.

Authors:  K Zemmour; A Tinland; M Boucekine; V Girard; S Loubière; N Resseguier; G Fond; P Auquier; L Boyer
Journal:  Sci Rep       Date:  2016-08-18       Impact factor: 4.379

9.  Beliefs about health, health risks and health expectations from the perspective of people with a psychotic disorder.

Authors:  Sally Hultsjö; Susanne Syren
Journal:  Open Nurs J       Date:  2013-08-20

10.  Professionals' perception on the management of patients with dual disorders.

Authors:  Carlos Roncero; Néstor Szerman; Antonio Terán; Carlos Pino; José María Vázquez; Elena Velasco; Marta García-Dorado; Miguel Casas
Journal:  Patient Prefer Adherence       Date:  2016-09-19       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.